ModernMedicine Resource Center More Topics

Hepatology Resource Center

DAAs safer, more tolerable than interferon for HCV infectionsResearchers find that direct-acting antivirals are better tolerated in patients with hepatitis C virus infections vs. interferon-based therapy.
Elimination of hepatitis B and C now feasibleA new report finds that hepatitis B and C can be eliminated as a public health problem.
Simeprevir, sofosbuvir combo treats HCV patients with cirrhosisThe protease and polymerase inhibitor proved effective and well tolerated in patients with hepatitis C virus and cirrhosis, according to a new study.
Perinatal HCV transmission needs national conversationA new study highlights the need for hepatitis C virus screening of pregnant women to identify HCV-infected children and direct them to proper care. A significant number of babies born to women who are infected with the hepatitis C virus (HCV) remain untested for perinatal infections, according to a new study.
Some HCV patients still difficult to treatDirect-acting antiviral (DAA) agents appear to have a less robust effect in “difficult-to-treat” patients, according to new research.
Real-world factors aid HCV patient treatment decisionsA new study explores what lifestyle hepatitis C virus (HCV) patients consider when directing their course of treatement.
HCV infection raises risk of developing Parkinson’sA new study indicates that infection with the hepatitis C virus (HCV) significantly increases the risk of developing Parkinson’s Disease.
Antiviral combination eradicates HCV in advanced liver diseaseThe use of sofosbuvir and velpatasvir successfully treated hepatitis C virus infection in 90% of advanced liver disease patients, a new study notes.
Direct-acting antivirals could reduce HCV prevalence by 80%A new study finds that novel direct-acting antiviral therapies might reduce the prevalence of hepatitis C virus and, with enhanced screening and treatment, potentially end infections altogether.
Earlier HCV treatment improves cost effectiveness of care
Earlier HCV treatment improves cost effectiveness of careTreating hepatitis C virus (HCV) infection at early stages of fibrosis improves health outcomes and is cost-effective, a new study finds.